Earnings Call Insights: AngioDynamics (ANGO) Q3 FY2026
Management view
- “Our third quarter was strong across the board,” James Clemmer said, adding that results were “led by impressive growth in our Med Tech segment” and that the company is “once again raising our full year guidance
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.